Source: PR-INSIDE.COM

Press Release: Promedior : New market study, "Promedior, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile", has been published

(PR-inside.com) Promedior, Inc. (Promedior) is a biotechnology company. The company develops therapeutic products for the treatment of fibrotic disorders and diseases. Its products under clinical development include PRM-151, and PRM-167. Promedior's products are used in the treatment of idiopathic pulmonary fibrosis, myelofibrosis, systemic fibrotic diseases, age-related macular degeneration, and retinal fibrovascular diseases. The company's PRM-151 is a recombinant form of human pentraxin-2 protein (rhPTX-2) that is formulated for intravenous injection. Its PRM-167 drug is developed for intravitreal delivery in retinal fibrovascular diseases. The company also develops formulation of Pentraxin-2 therapeutics for inhaled local delivery in lung diseases. Promedior is headquartered in ..

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Estimated Annual Revenue

Estimated Employees

Jason Lettmann's photo - CEO of Promedior

CEO

Jason Lettmann

CEO Approval Rating

90/100

Promedior is a clinical-stage biotechnology company that develops and commercializes novel therapeutics for the treatmen... Read more